Noramco signs AMPAC to top up API and intermediates supply

By Flora Southey

- Last updated on GMT

AMPAC Fine Chemicals will boost Noramco Inc.’s supply of active pharmaceutical ingredients and intermediates to make abuse prevention and attention deficit disorder treatments, and cannabinoids.

According to the strategic partnership agreement, AMPAC Fine Chemicals (AFC) will supply Noramco with certain US Drug Enforcement Administration (DEA) controlled substances from its manufacturing plant in Petersburg, Virginia.

The US DEA Schedule II and III​ drugs include substances with a high, or moderate to low potential for physical and psychological dependence, respectively.

According to Noramco, the Virginia facility will complement its in-house capabilities in Delaware to provide the extra capacity it needs to meet growing demand. 

A Noramco spokesperson told us the APIs in the agreement are key for addiction treatment and abuse deterrent formulations.

“Specifically, the APIs and intermediates for Buprenorphine HC1, Naltrexone, Naltrexone HC1, and Naloxone,” ​we were told.

A move to cannabinoids

Traditionally an opioid API-focused firm, Noramco added cannabinoids​ to its portfolio last year, in response to drug industry demand.

Now both firms make intermediates and APIs for the cannabinoid family, including cannabidiol and dronabinol.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more